{"brief_title": "Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome", "brief_summary": "The purpose of this study is to determine the safety and efficacy of TLK199 in patients with myelodysplastic syndrome (MDS).", "condition": "Myelodysplastic Syndromes", "intervention_type": "Drug", "intervention_name": "TLK199 HCl Liposomes for Injection", "criteria": "Inclusion Criteria: - Histologically or cytologically confirmed diagnosis of MDS - Adequate liver and kidney function - Ineligible for, or refusing, allogeneic bone marrow transplant - At least 18 years of age - Discontinuation of growth factors (e.g., G- CSF) at least 2 weeks prior to study entry Exclusion Criteria: - Failure to recover from any prior surgery, or any major surgery within 4 weeks of study entry - Pregnant or lactating women - History of allergy to eggs - Other investigational drugs within 14 days of study entry - Chemotherapy, radiotherapy or immunotherapy within 14 days of study entry - Concomitant steroids or hormones for the treatment of neoplasms", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00035867.xml"}